Nocturnal Blood Pressure and Hypertension - Central and Peripheral 24-h Blood Pressure.

NCT ID: NCT02078765

Last Updated: 2014-10-09

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 150 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2014-01-31
• Study Completion Date: 2017-12-31

Brief Summary

A new study have shown that high night time blood pressure (BP) and/or non-dipping (lack of fall in BP during night time) is a strong predictor for the risk of cardiovascular disease and mortality in patients with hypertension. Three factors seem to affect the night time BP: chronic kidney disease, obstructive sleep apnea (OSA) and the way ambulatory blood pressure is monitored.

Hypothesis:

Central 24-h blood pressure monitoring is a better way of monitoring blood pressure than conventional peripheral monitoring.

In hypertension, chronic kidney disease and obstructive sleep apnea (OSA) the night time blood pressure is elevated, and is OSA the elevation is correlated to the severity of OSA.

In OSA the kidneys handling of salt and water is disturbed. In OSA there is disturbances in hormonal balance.

Detailed Description

75 patients with hypertension and chronic kidney disease (CKD I-II) and 75 healthy subjects is examined with both central and peripheral 24 hours blood pressure monitoring, 1 night home polygraphy to determine whether the subject has obstructive sleep apnea (OSA), and if so the degree (apnea hypopnea index, AHI), blood and urine samples to determine levels of urine aquaporine2 (u-AQP2), urine endothelial sodium channel (u-EnaC), plasma renin concentration (PRC), plasma angiotensin II (p-AngII), plasma aldosterone (p-aldosterone), plasma vasopressin (p-AVP) and plasma endothelin (p-endothelin).

Hypothesis:

Central 24-h BP monitoring provides another measure of daily fluctuations in blood pressure than peripheral 24-h BP monitoring, because this measurement is painless and does not interfere with activities in the daytime or night-time sleep.

In hypertension, chronic kidney disease and OSA the decease in nocturnal BP is lower than i healthy subjects.

In OSA the decrease in the nocturnal BP is inversely correlated with the severity of OSA.

In OSA is the renal tubular absorption of water and sodium abnormal with increased tubular absorption of water with AQP2 and of sodium by ENAC.

In OSA, there is increased activity of the renin-angiotensin-aldosterone system, increased endothelin in plasma and increased vasopressin in plasma.

Conditions

Hypertension; Chronic Kidneys Disease; Obstructive Sleep Apnea

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: CROSS_SECTIONAL

Study Groups

hypertension

75 patients with hypertension and chronic kidney disease (CKD stage I-II)

No interventions assigned to this group

healthy subjects

75 healthy subjects

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Chronic kidney disease (CKD stage I and II), estimated glomerule filtration rate (eGFR) 60-90 ml/min/1.73 m2 or eGFR> 90 ml/min/1.73 m2 and proteinuria or other signs of kidney damage.
• Hypertension (BP by ambulatory or home blood pressure> 135/85 mmHg, or consultation blood pressure> 140/90 mmHg).
• Both men and women
• 55-70 years
• A completed consent form

• Healthy subjects men and women
• age 55 - 70 years
• Body mass index within the normal range, between 18.5 to 25.0 kg/m2

Exclusion Criteria

• Lack of desire to participate
• In the treatment of OSA
• Malignant disease
• Abuse of drugs or alcohol
• Pregnant and breastfeeding
• Incompensated heart failure
• Atrial fibrillation
• Liver disease (Alanine aminotransferase (ALT)> 200)
• Severe chronic obstructive pulmonary disease (COPD) (Forced expiratory volume in 1 second <50% predicted)
• eGFR <60 ml/min/1.73 m2
• Blood pressure difference between the right and left arm> 10/10 mmHg

Group 2 - Healthy subjects

• Arterial hypertension, ambulatory blood pressure> 130 mmHg systolic and / or 80 mmHg diastolic.

• a history or clinical signs of cardial, pulmonary, hepato, renal, endocrine, cerebral or neoplastic disorders
• Alcohol abuse, ie. > 14 drinks / week for women and> 21/uge for men
• Substance abuse
• Medical treatment apart from oral contraceptives
• Smoking
• Pregnancy or breastfeeding
• Lack of desire to participate
• Clinically significant, discrepant results of blood or urine sample at inclusion study (B-hemoglobin and B-White blood cell count, p-sodium, p-potassium, p-creatinine, p-ALT, p-bilirubin , p-Alkaline phosphatase, p-cholesterol, p-albumin or b-glucose and urine for hematuria, albuminuria or glucosuria)
• Clinically significant variations in the electrocardiogram
• Blood Donation for the past month preceding the day on the first attempt sequence
• Blood pressure difference between the right and left arm> 10/10 mmHg.

• Minimum Eligible Age: 55 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Erling Bjerregaard Pedersen

OTHER

Sponsor Role: lead

Responsible Party

Erling Bjerregaard Pedersen

professor

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

Department of Medical Research and Medicine, Holstebro Regional Hospital

Holstebro, Holstebro, Denmark

Countries

Denmark

Other Identifiers

M-2013-303-13

Identifier Type: OTHER

Identifier Source: secondary_id

BGH-2-2013

Identifier Type: -

Identifier Source: org_study_id